APVO News and Press, Aptevo Therapeutics Inc. From 03/31/21

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Ag...

Today, we take our first look at a small developmental concern based out of Seattle called Aptevo. The stock was in the news of late last year,  thanks to a buyout offer and some trial developments. A full analysis on Aptevo Therapeutics follows in the paragraphs below. ...

Stockholders Are Not Required to Take Any Action at this Time SEATTLE, WA / ACCESSWIRE / February 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ an...

Click here to read the previous top NASDAQ biotech stocks article. It’s been a stellar year for the NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ), which started at 3,763.05 points in January and reached a high of 4,811.03 points on December 15. While the inde...

Aptevo went up hugely on positive phase 1 data in AML. The company develops bispecific antibodies against cancer. Although early stage, this is a definite candidate for my watchlist. For further details see: Aptevo: Positive Early Stage Data Makes This Highly Interesting...

Aptevo Therapeutics ([[APVO]] +10.0%) announces that it has expanded its ADAPTIR bispecific platform technology to include a new multi-specific platform technology, ADAPTIR-FLEX™. Aptevo also announced that it has developed a new bispecific candidate, APVO442, that utilizes ADAPTI...

New Bispecific Therapeutic Candidate APVO442 uses ADAPTIR-FLEX Platform Technology APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate Cancer SEATTLE, WA / ACCESSWIRE / December 2, 2020 / Aptevo Therapeutics Inc. ("Aptevo" or the "Compan...

SEATTLE, WA / ACCESSWIRE / November 19, 2020 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received an ...

Gainers: Naked Brand (NAKD) +116%.Phoenix New Media (FENG) +48%.Titan Pharmaceuticals (TTNP) +36%.HighPoint Resources (HPR) +32%.Arcimoto (FUV) +32%.Ayro (AYRO) +29%.CIIG Merger (CIIC) +27%.Aptevo Therapeutics (APVO) +27%.Sonos (SONO) +27%.Blink Charging (BLNK) +23%.Losers: Ebang In...

Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,&#x...